Search Results

Panbela today announced an Issue Notification for the Chinese patent 201980010826.7 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

Seneca Therapeutics, Inc. announced the publication of an abstract “Oncolytic Seneca Valley Virus overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model” at the upcoming American Association for Cancer Research meeting in New Orleans, LA.

Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company has entered into a collaboration with Syngene International Limited

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the presentation of two posters with research results on TNX-1700 (recombinant TFF2 – albumin fusion peptide) at the American Association for Cancer Research (AACR) Annual Meeting, held April 14-19, 2023, in Orlando, Fla.

Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation

Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce it is now supplying the AirClean® AC600 Series of PCR Workstations.

Maryland, MD: Syngene, a world-leading manufacturer of image analysis solutions, is pleased to announce it has entered a sponsorship agreement with Tufts Launchpad | BioLabs developed by Tufts University to be Boston’s premier fully equipped, co-working and shared lab space for biotech start-ups.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company’s lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model.